News & Analysis on Clinical Trial Services & Contract Research And Development
Phathom, Terrie Curran
By Vassia Barba
- Last updated on
Αs Celgene’s acquisition by Bristol-Myers Squibb moves to completion, the former company’s president of Global Inflammation and Immunology, Terrie Curran, was announced as the CEO of the biopharmaceutical company, Phathom Pharmaceuticals.
Phathom is a developer of treatments for gastrointestinal diseases, founded earlier this year through a collaboration between Takeda and the venture capital firm, Frazier Healthcare Partners. The company plans to initiate Phase III clinical studies for its candidate, vonoprazan, later this year.
Curran will take on her new role, succeeding Phathom’s current CEO, David Socks, after the completion of Celgene’s acquisition, expected by the end of the year, while she will also join Phathom’s board of directors. Following the transition, Socks, who is also one of Phathom’s co-founders, will become the company’s interim CFO.
Prior to joining Celgene in 2013, Curran was the SVP and general manager of Global Women’s Health at Merck. The executive currently also serves on the board of Myovant Sciences, while she has previously served on the board of H. Lundbeck.